T&W Medical A/S
T&W Medical A/S is a Danish investment holding company focused on equity investments in medtech and life science businesses. Through its group interests, it is exposed to products and technologies related to hearing care, epilepsy care, and other medical and health-related solutions.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2023–2025
Liiketoiminta
Osuus liikevaihdostaHearing aids and associated hearing-care products sold through operating group interests.
Implantable and EEG-based devices and solutions for epilepsy and neurological care.
Ownership interests in medtech and life science companies and related investments.
Asiakkaat
The company serves end users and healthcare channels through its operating interests, especially people needing hearing solutions and patients with epilepsy-related care needs. Its products are also sold through audiology professionals, clinics, and independent distributors that support diagnosis, fitting, and ongoing device use.
Buy hearing aids and related products to improve daily hearing and communication.
Purchase, fit, and service hearing solutions for end users.
Buy hearing products for resale in local markets and channel coverage.
Use EEG and implantable devices for monitoring and managing epilepsy care.
Strategia
T&W Medical’s stated focus is to own and invest in high-technology medtech and life science companies that improve quality of life. The portfolio approach combines long-term ownership with exposure to specialized healthcare technologies and established commercial platforms.
The holding company model depends on developing and supporting businesses with durable medical technology positions.
Global distribution and product adoption are central to monetizing specialized healthcare technologies.
Maantiede
The group has a global operating footprint through its hearing-care interests, with products sold worldwide via own sales companies and independent distributors. Denmark is the company’s home base, while the underlying businesses depend on international markets, supply chains, and regulatory approvals across multiple countries.
Riskit
The business is exposed to operating-company risks from medtech commercialization, including competition, product development, and regulatory approval requirements. It also faces supply-chain, cyber, foreign exchange, and refinancing risks through its underlying group interests and international operations.
- Supply chain disruptionVaikutus: KorkeaTodennäköisyys: Korkea
The operating businesses rely on international suppliers for components.
Kohdistuu - Regulatory and approval riskVaikutus: KorkeaTodennäköisyys: Kohtalainen
Medical devices require approvals across jurisdictions, and standards can change over time.
Kohdistuu: Hearing aids and implantable devices
- Cybersecurity and IT disruptionVaikutus: KorkeaTodennäköisyys: Kohtalainen
Ransomware or data breaches can halt operations and affect sensitive medical information.
Kohdistuu: Production systems and patient data
- Refinancing and interest rate riskVaikutus: KorkeaTodennäköisyys: Kohtalainen
Floating-rate debt and maturity refinancing can pressure cash flow if markets tighten.
Kohdistuu: Senior secured loans
Kirjanpito
Harkinnanvaraiset erätAmortization of acquired identifiable assets can materially depress EBIT and distort year-to-year comparisons.
Vaikutus: Reported operating profit
Non-recurring acquisition-related or other exceptional costs are excluded from adjusted measures, affecting underlying performance interpretation.
Vaikutus: Adjusted EBITDA and EBIT
Medtech acquisitions and technology assets require impairment testing if performance weakens.
Vaikutus: Asset carrying values and earnings
Päivitetty: 24.10.2026